首页> 外文期刊>The Indian journal of tuberculosis >INFLUENCE OF DRUG SUSCEPTIBILITY ON TREATMENT OUTCOME AND SUSCEPTIBILITY PROFILE OF 'FAILURES' TO CATEGORY II REGIMEN
【24h】

INFLUENCE OF DRUG SUSCEPTIBILITY ON TREATMENT OUTCOME AND SUSCEPTIBILITY PROFILE OF 'FAILURES' TO CATEGORY II REGIMEN

机译:药物敏感性对II类方案“失败”的治疗结果和易感性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To assess the influence of drag resistance on treatment outcome among patients treated with Category-II regimen and document drug susceptibility pattern of "Failures" to this regimen.Design: A retrospective analysis of patients registered from May 1999 through December 2004.Results: Treatment success was 42% among 572 patients and was similar among patients with fully susceptible or resistant but non-MDR organisms (41% of 254 and 40% of 128 patients, respectively). Among 49 MDR-TB patients, 27% had successful treatment outcome. The failure rates among patients with fully susceptible, resistant but non-MDR and MDR bacilli, were 6%,12% and 27% respectively. Default was significantly higher among males (53% vs.34%: p<0.01) smokers (57% vs., 36%: p 0.001), alcoholics (58% vs.. 39%: p <0 001) and patients with higher initial smear grading (2+ or 3+, 56% vs. scanty or 1+,44%: p <0.01). DST results were available for 60% (31 of 52) of failures and 10 had MDR-TB.Conclusion: The low success rate to the re-treatment regimen was mainly due to non-compliance Failure was observed among 9% of patients and MDR-TB was 32% among Category II failures. The currently recommended Category II regimen appears to be adequate for majority of re-treatment cases.
机译:目的:评估阻力阻力对II类方案治疗患者的治疗效果的影响,并记录该方案“失败”的药物敏感性模式。设计:回顾性分析1999年5月至2004年12月注册的患者。在572例患者中,治疗成功率为42%,在完全易感或耐药但非耐多药生物体的患者中,治疗成功率相似(分别为254%患者和254患者中的41%和128%)。在49名耐多药结核病患者中,有27%的治疗结果成功。完全易感,耐药但非耐多药和耐多药杆菌的患者的失败率分别为6%,12%和27%。男性吸烟者(53%vs.34%:p <0.01),吸烟者(57%vs. 36%:p 0.001),酗酒者(58%vs. 39%:p <0.001)的违约率明显更高较高的初始涂片分级(2+或3+,56%vs.稀疏或1 +,44%:p <0.01)。 DST结果可用于60%的失败(52例中的31例)和10例MDR-TB。结论:重新治疗方案的成功率低主要是由于不依从性在9%的患者和MDR中观察到失败-TB在II类故障中占32%。目前推荐的II类治疗方案似乎适合大多数再治疗病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号